Is Weed Legal in Brazil? Understanding Brazil Cannabis and Marijuana Laws (2026)

Brazil permits regulated medical cannabis access and has decriminalized cannabis possession for personal use. It has not legalized a recreational retail market. The Supreme Federal Court’s reference to 40 grams or six female plants is a rebuttable presumption of personal use, not an absolute legal allowance or an automatic trafficking threshold.

Medical rules changed substantially in 2026. A new framework for cannabis products took effect in May, while regulated cultivation rules took effect in August. These measures require authorizations and do not give every patient, pharmacy, or company permission to grow or sell cannabis.

Is Cannabis Decriminalized in Brazil?

Yes, for personal possession of cannabis. In RE 635659, Theme 506, the Supreme Federal Court removed the criminal character of possession for personal consumption while retaining its unlawful, noncriminal status. Seizure, warnings, and educational measures remain possible. The decision concerns cannabis, not a general decriminalization of all drugs.

The court established a presumption of personal use for up to 40 grams or six female plants. Evidence of dealing can rebut that presumption even below those quantities. Conversely, exceeding them does not automatically make someone a trafficker: a court can still find personal use based on sufficient evidence. The circumstances of possession remain important.

This distinction is more accurate than saying that a small amount is legal or that every larger amount is a crime. The ruling did not authorize recreational shops, public consumption everywhere, or supply to other people.

Is Recreational Cannabis Legal?

No licensed nationwide recreational market has been created. Decriminalization of personal possession and regulation of medical products are separate developments. Neither allows a seller to treat an ordinary recreational transaction as a medical sale.

Brazil’s principal drug and medicines rules are federal. Local public-health services, sanitary licensing requirements, and individual court orders can nevertheless affect practical access. It is misleading to assume that every patient has identical access across the country.

How Can Patients Access Medical Cannabis?

Patients should distinguish registered medicines, cannabis products with a special sanitary authorization, and exceptional personal imports. These are different regulatory routes, with different evidence and access requirements. A product authorized under a special route should not automatically be described as a fully registered medicine.

Anvisa confirms that RDC 1,015/2026 took effect on May 4, 2026, replacing the previous RDC 327/2019 framework for manufacturing and importing cannabis products. Under the resolution, licensed doctors and dentists following the patient clinically may prescribe these products when there is no satisfactory alternative using medicines regularized in Brazil.

The permitted routes are inhalation, oral, buccal, sublingual, and dermatological administration. Products above 0.2% THC are restricted to serious debilitating or life-threatening diseases and are contraindicated for people under 18, pregnant patients, and those breastfeeding. The rule requires a benefit-risk assessment for older patients and specified cannabis-use histories. These provisions concern the special cannabis-product category, rather than every conceivable cannabinoid medicine.

Products at or below 0.2% THC use a Special Control Prescription, while those above that level require a type A prescription notification. Anvisa’s May 2026 alignment rules address controlled-product classification, labeling, dispensing, and exports. Lower THC does not make these products over-the-counter goods.

Article 72 envisages pharmacy compounding with plant-derived pharmaceutical CBD as the sole active ingredient, subject to separate Anvisa regulation. It should not be read as an unconditional authorization for any compounding pharmacy to prepare cannabis extracts or THC formulas.

Can Patients Import Cannabis Products?

Yes, through the exceptional personal-import route when its conditions are met. The official Anvisa service requires an application and prescription from a legally qualified professional. Authorization is valid for two years and covers the patient’s own treatment; it is not a resale license or proof of full medicine registration.

Anvisa’s personal-import guidance does not authorize cannabis plants, plant parts, or flowers. Rules allowing licensed businesses to obtain plant material for an authorized production chain do not extend that permission to ordinary patient imports.

Can Cannabis Be Grown in Brazil for Medicine?

Yes, through authorized arrangements. The August 2026 cultivation framework creates an administrative route for regulated production; it was not the first time any Brazilian patient or association had obtained legal protection to cultivate through the courts.

Anvisa’s implementation guidance explains that RDC 1,013/2026 covers cultivation by legal entities of varieties producing no more than 0.3% THC, exclusively for medical, pharmaceutical, or research purposes. RDC 1,012/2026 provides a separate research route. Cultivation may begin only after Anvisa grants the required Special Authorization and other applicable requirements are met.

Projects must address sanitary inspection, security, traceability, control, and monitoring. Local sanitary authorities and the Ministry of Agriculture may impose requirements within their responsibilities. A regulation taking effect is not evidence that a particular producer has received its authorization or started supplying patients.

RDC 1,014/2026 creates a supervised experimental framework for nonprofit patient associations. As Anvisa explains, it includes monitoring and quality controls and does not authorize commercialization. An association’s existing court protection and its eligibility for a regulatory project must be assessed separately.

Can I Grow Cannabis at Home?

The six-female-plant presumption in the personal-use ruling is not an unrestricted home-growing license. Purpose and evidence matter, and plants can remain subject to seizure under the noncriminal framework. The 2026 production regulations do not create a general individual medical home-grow permit.

Medical cultivation has also been protected through case-specific court decisions. In its August 2026 review of cannabis precedents, the Superior Court of Justice describes protective orders for patients cultivating exclusively for documented treatment. Such an order depends on the patient’s circumstances and its own terms; another patient’s ruling is not automatic permission for everyone.

Are Hemp and CBD Legal?

The low-THC cultivation route is tied to medical, pharmaceutical, or research purposes. It does not establish unrestricted hemp farming for textiles, construction materials, food, or recreational flower. The 0.3% crop threshold must also be distinguished from the 0.2% THC threshold used in the cannabis-product prescribing rules.

CBD can be accessed through the appropriate regulated treatment route. It is not generally a freely marketable wellness ingredient simply because it is non-intoxicating. Patients should confirm the exact product’s authorization or personal-import status, prescription requirements, and availability with their clinician and supplier. Domestic cultivation may change supply over time, but it does not guarantee immediate availability or lower prices.

Brazil’s research history includes the work of Elisaldo Carlini. Scientific interest and a lawful prescription are important, but neither removes the need to comply with the relevant product rules.

Could the Law Change Again?

The Chamber of Deputies’ record for PEC 45/2023 lists the proposed constitutional amendment on unauthorized drug possession as awaiting formation of a temporary committee. The proposal seeks criminalization while distinguishing users from traffickers. It is a pending proposal, not an enacted replacement for the Supreme Court’s ruling.

Readers should separate legislation in force, court decisions, regulatory authorizations, and political proposals. Regional comparisons are available in our guides to Argentina and Colombia, whose rules do not apply in Brazil.